drugset / Trial / NCT06953063
A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of DA-302168S tablets in overweight and obese adults.
Timeline
- Start
- 2025-05-15
- Primary completion
- 2025-12-15
- Completion
- 2025-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-302168S | Small molecule | 5 mg | Oral |
| Subject | DA-302168S | Small molecule | 10 mg | Oral |
| Subject | DA-302168S | Small molecule | 20 mg | Oral |
| Subject | DA-302168S | Small molecule | 30 mg | Oral |
Indications
No indication recorded.